Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

11.2K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
11.2K
Glaucoma: Overview01:25

Glaucoma: Overview

1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

50
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
50
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

247
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
247

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of the Zoster Eye Disease Study Using Original End Point Criteria.

Ophthalmology·2025
Same author

Bayesian Analysis of Valacyclovir Treatment Effect in the Zoster Eye Disease Study.

Ophthalmology·2025
Same author

Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus: The Zoster Eye Disease Randomized Clinical Trial.

JAMA ophthalmology·2025
Same author

Low-Dose Valacyclovir for Postherpetic Neuralgia in the Zoster Eye Disease Study: A Randomized Clinical Trial.

JAMA ophthalmology·2025
Same author

Impact of rapid blood culture identification PCR panel on optimal antibiotic use in methicillin-susceptible <i>Staphylococcus aureus</i> bacteremia.

Microbiology spectrum·2024
Same author

Impact of BioFire® Blood Culture Identification (BCID) panels on antibiotic management of bacteremia due to select organisms.

Diagnostic microbiology and infectious disease·2024

Related Experiment Video

Updated: Apr 12, 2026

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

4.5K

Persistent dilemmas in zoster eye disease.

Elisabeth J Cohen1, Jason Kessler2

  • 1Department of Ophthalmology, New York University School of Medicine, NYU Langone Medical Center, New York, New York, USA.

The British Journal of Ophthalmology
|May 14, 2015
PubMed
Summary

Herpes zoster ophthalmicus (HZO) is a serious eye condition caused by varicella-zoster virus reactivation. A proposed trial will investigate suppressive antiviral treatment to prevent long-term complications like chronic eye disease and postherpetic neuralgia.

Keywords:
Treatment other

More Related Videos

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK
07:27

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK

Published on: December 18, 2012

12.5K
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

2.0K

Related Experiment Videos

Last Updated: Apr 12, 2026

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

4.5K
Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK
07:27

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK

Published on: December 18, 2012

12.5K
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

2.0K

Area of Science:

  • Ophthalmology
  • Virology
  • Infectious Diseases

Background:

  • Herpes zoster ophthalmicus (HZO) is a vision-threatening reactivation of varicella-zoster virus (VZV).
  • HZO affects all age groups, with increasing incidence globally, impacting immunocompetent individuals significantly.
  • Current zoster vaccine (ZV) recommendations and physician endorsement present barriers to widespread use, with debated optimal timing.

Purpose of the Study:

  • To address the need for evidence regarding prolonged antiviral treatment for HZO.
  • To investigate the efficacy of suppressive antiviral therapy in preventing chronic ocular complications and postherpetic neuralgia (PHN).

Main Methods:

  • A proposed randomized controlled trial (RCT) is designed to evaluate suppressive antiviral treatment.
  • The study will draw parallels with herpes simplex virus (HSV) eye infections where similar treatments are standard of care.

Main Results:

  • Limited evidence currently exists for the benefits of prolonged antiviral treatment in HZO.
  • Zoster reactivation is associated with chronic active VZV infection, suggesting a rationale for suppressive therapy.

Conclusions:

  • There is a need for further research into optimal treatment strategies for HZO.
  • Suppressive antiviral treatment may offer a novel approach to mitigate chronic sequelae of HZO, including ocular disease and PHN.